ClinVar Miner

Submissions for variant NM_001114753.3(ENG):c.1470dup (p.Asp491fs)

dbSNP: rs1830385077
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001069205 SCV001234358 pathogenic Hereditary hemorrhagic telangiectasia 2023-10-12 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Asp491Argfs*10) in the ENG gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ENG are known to be pathogenic (PMID: 15879500). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with hereditary hemorrhagic telangiectasia (PMID: 10625079, 15712271). This variant is also known as +A FS at 1471. ClinVar contains an entry for this variant (Variation ID: 862475). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV001585973 SCV001818272 pathogenic not provided 2022-11-11 criteria provided, single submitter clinical testing Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 10625079, 11440987, 17384219, 16752392, 15024723, 15712271)
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV001803223 SCV002047887 pathogenic Telangiectasia, hereditary hemorrhagic, type 1 2020-11-10 criteria provided, single submitter clinical testing The ENG c.1470dupA; p.Asp491ArgfsTer10variant, also known as c.1470_1471insA, is reported in the literature in individuals and families affected with hereditary hemorrhagic telangiectasia (Abdalla 2005, Cymerman 2000, Gedge 2007). This variant is also reported in ClinVar (Variation ID: 862475), and is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This variant causes a frameshift by inserting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Abdalla SA et al. Novel mutations and polymorphisms in genes causing hereditary hemorrhagic telangiectasia. Hum Mutat. 2005 Mar;25(3):320-1. Cymerman U et al. Identification of hereditary hemorrhagic telangiectasia type 1 in newborns by protein expression and mutation analysis of endoglin. Pediatr Res. 2000 Jan;47(1):24-35. Gedge F et al. Clinical and analytical sensitivities in hereditary hemorrhagic telangiectasia testing and a report of de novo mutations. J Mol Diagn. 2007 Apr;9(2):258-65.
Ambry Genetics RCV002393333 SCV002697951 pathogenic Cardiovascular phenotype 2017-11-13 criteria provided, single submitter clinical testing The c.1470dupA pathogenic mutation, located in coding exon 12 of the ENG gene, results from a duplication of A at nucleotide at position 1470, causing a translational frameshift with a predicted alternate stop codon (p.D491Rfs*10). This mutation was described in a newborn and his father (who had a clinical diagnosis of hereditary hemorrhagic telangiectasia - HHT), and in both individuals decreased levels of fully processed endoglin were observed (Cymerman U et al, Pediatr. Res. 2000 Jan; 47(1):24-35). This mutation was also detected (referred to as c.1470_1471insA) in one patient of a Japanese kindred with multiple family members affected with HHT (Dakeishi M et al, Hum. Mutat. 2002 Feb; 19(2):140-8). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute RCV001803223 SCV003921883 pathogenic Telangiectasia, hereditary hemorrhagic, type 1 criteria provided, single submitter clinical testing - Variant is predicted to cause nonsense-mediated decay (NMD) and loss of protein (premature termination codon is located at least 54 nucleotides upstream of the final exon-exon junction). - Variant is absent from gnomAD (both v2 and v3). - Other NMD-predicted variants comparable to the one identified in this case have very strong previous evidence for pathogenicity (ClinVar). - This variant has strong previous evidence of pathogenicity in unrelated individuals. It has been reported in at least five individuals with hereditary haemorrhagic telangiectasia (PMID: 12673790, ClinVar). Additional information: - Dominant negative and loss of function are known mechanisms of disease in this gene and are associated with hereditary haemorrhagic telangiectasia type 1 (HHT; MIM#187300). Loss-of-function variants have been reported, with missense variants shown to have both loss of function and dominant negative effects on protein activity (PMID: 25312062). - This gene is associated with autosomal dominant disease. - This variant is heterozygous. - This variant has been shown to be maternally inherited (by trio analysis).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.